Lithium hexamethyl disilazide solution - 1 M in tert-butyl methyl ether

CAS : 4039-32-1

Ref. 3D-FL146829

Informations sur le produit

• Nom: Lithium hexamethyl disilazide solution - 1 M in tert-butyl methyl ether
• Synonymes: 1,1,1,3,3,3-Hexamethyldisilazane lithium saltLithium bis(trimethylsilyl)amide, (Hexamethyldisilazane)lithium, 1,1,1,3,3,3-Hexamethyldisilazane Lithium Salt, 1,1,1-Trimethyl-N-(trimethylsilyl)silanamine lithium salt, Bis(trimethylsilyl)amide de lithium, Bis(trimethylsilyl)amidolithium, Disilazane, 1,1,1,3,3,3-hexamethyl-, Li deriv., Disilazane, 1,1,1,3,3,3-hexamethyl-, lithium salt, Hexamethyldisilazane lithium salt, Hexamethyldisilazide, Lithium, Lhmds, LiHMDS, Lithiobis(trimethylsilyl)amide, Lithiohexamethyldisilazane, Lithium bis(trimethylsilyl)amide, Lithium bis(trimethylsilyl)amide(1-), Lithium bis(trimethylsilyl)amine, Lithium hexamethyldisilazanate, Lithium hexamethyldisilazane, Lithium hexamethyldisilazanide, Lithium hexamethyldisilazide, Lithium, [bis(trimethylsilyl)amino]-, Lithiumbis(Trimethylsilyl)Amide, Lithiumbis(trimethylsilyl)amid, Litiobis(Trimetilsilil)Amida, N,N-Bis(trimethylsilyl)amine lithium salt, N-Lithiohexamethyldisilazane, Silanamine, 1,1,1-trimethyl-N-(trimethylsilyl)-, lithium salt (1:1), [1,1,1-Trimethyl-N-(trimethylsilyl)silanaminato]lithium
• CAS: 4039-32-1

Description

Lithium hexamethyl disilazide solution is an inhibitor drug that blocks the synthesis of pyrimidine compounds. It has been shown to be effective in congestive heart failure, hyperproliferative diseases such as pancreatitis and dyslipoproteinemia, coronary heart diseases, and HIV infection. Lithium hexamethyl disilazide solution binds to the cb2 receptor on the surface of activated T cells, which inhibits their ability to cause inflammation or autoimmune disease. This drug also has nitrogen atoms that are reactive and asymmetric, making it a good candidate for an inhibitor drug.

• Marque: Biosynth

Propriétés chimiques

• Masse moléculaire: 167.33 g/mol
• Formule: C₆H₁₈LiNSi₂
• Degré de pureté: Min. 95%